"The open-label basket design of the Aurora study will enable us to efficiently evaluate the safety and efficacy of GTX-102 in younger and older patients with Angelman syndrome and those with other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback